Axelife® SAS is a French company that, since its formation in 2010, has specialized in the field of health. It designs and develops medical devices, and its flagship product, the “pOpmètre®”, is a device that diagnoses arteriosclerosis and accelerated arterial aging.
The pOpmètre® is the culmination of 10 years of research and development. This medical device is based on a new medical approach and innovative technology.
Our innovative approach
For more than 50 years, blood pressure, diabetes, and cholesterol have been used as prevention parameters for cardiovascular disease. However, only 50% of individuals with hypertension are treated, and 50% of these are not on target. Mercury is no longer permitted, and electronic devices are not consistent.
20% of heart attack victims do not smoke or suffer from diabetes, high blood pressure, or high levels of cholesterol. For this reason, a new approach to screening cardiovascular pathologies is needed.
Arterial aging, as as measured by the pOpmètre® using Pulse Rate Velocity (PWV), more accurately predicts stroke and heart attack than diabetes, blood pressure or cholesterol combined.
PWV measurements are recommended by the European and French societies of Hypertension and Cardiology. Recognized since last century, this measure was long, tedious and expensive.
Neither ECG or ultrasound serve as screening tools, and coronary CT angiography even less so! In addition, mercury, which served as the basis of diagnosis, is now prohibited.
The pOpmètre® is a breakthrough innovation. This medical device reveals the age of the arteries by measuring Pulse Wave Velocity in 2 minutes.
For healthcare professionals, the pOpmètre® assists in screening for cardiovascular disease. With 150,000 heart attacks per year and 140,000 strokes per year, it is urgent to detect, prevent, and cure these conditions. With pOpmètre®, mass screening is feasible.
The pOpmètre® is also a tool for help in making decisions and choosing treatment. For hypertension, 30% are cases of false positives and 20% are cases of masked hypertension or false negatives.
Finally, the pOpmètre® is a great tool for the therapeutic education of patients, with arterial age serving as a deciding factor.
PWV is to hypertension what HbA1c is to diabetes.
With its extensive expertise in the development of medical devices, Axelife SAS is consolidating its presence in the field of cardiovascular prevention devices with the iHeartWatch®.
Most recent publications
BACKGROUND: Pulse wave velocity (PWV) is a marker of arterial stiffness. The aim of the present study was to compare PWV in patients with type 2 diabetes mellitus (T2DM) or obesity and healthy subjects in an outpatient setting. METHODS: A cross-sectional study was conducted in patients with obesity without T2DM (n = 37), T2DM without obesity (n = 40),…
Evaluation of arterial stiffness by finger-toe pulse wave velocity: optimization of signal processing and clinical validation
Carotid-femoral pulse wave velocity (PWV) (cf-PWV) is the gold standard for measuring aortic stiffness. Finger-toe PWV (ft-PWV) is a simpler noninvasive method for measuring arterial stiffness. Although the validity of the method has been previously assessed, its accuracy can be improved. ft-PWV is determined on the basis of a patented height chart for the distance and the pulse transit time (PTT) between the finger and the toe pulpar arteries signals (ft-PTT).
Arterial perfusion defects are a risk factor for anastomotic leakage (AL) following colorectal surgery. Measuring arterial stiffness using pulse wave velocity (PWV) is known to reflect the performance of the arterial network. The objective of this study was to assess the predictive value of PWV for AL after colorectal surgery.